Robert Henry Mach1, Kenneth Theodore Wheeler. 1. Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA. rhmach@mir.wustl.edu
Abstract
The sigma-2 (sigma(2)) receptor is proving to be an important protein in the field of cancer biology. The observations that sigma(2) receptors have a 10-fold higher density in proliferating tumor cells than in quiescent tumor cells, and that sigma(2) receptor agonists are capable of killing tumor cells via apoptotic and non-apoptotic mechanisms, indicate that this receptor is an important molecular target for the development of radiotracers for imaging tumors using techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and for the development of cancer chemotherapeutic agents. In spite of recent promising results towards achieving these goals, research in this field has been hampered by the fact that the molecular identity of the protein sequence of the sigma(2) receptor is currently not known. Consequently, most of what is known about this protein has been obtained using either radiolabeled or fluorescent probes for this receptor, or biochemical analysis of the effect of sigma(2) selective ligands on cells growing under tissue culture conditions. This article provides a review of the development and use of sigma(2) receptor ligands, and how these ligands have been used with a variety of in vitro and in vivo models to gain a greater understanding of the role this receptor plays in cancer.
The sigma-2 (sigma(2)) receptor is proving to be an important protein in the field of cancer biology. The obn class="Chemical">servations that sigma(2) receptors have a 10-fold higher density in proliferating tumor cells than in quiescent tumor cells, and that sigma(2) receptor agonists are capable of killing tumor cells via apoptotic and non-apoptotic mechanisms, indicate that this receptor is an important molecular target for the development of radiotracers for imaging tumors using techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and for the development of cancer chemotherapeutic agents. In spite of recent promising results towards achieving these goals, research in this field has been hampered by the fact that the molecular identity of the protein sequence of the sigma(2) receptor is currently not known. Consequently, most of what is known about this protein has been obtained using either radiolabeled or fluorescent probes for this receptor, or biochemical analysis of the effect of sigma(2) selective ligands on cells growing under tissue culture conditions. This article provides a review of the development and use of sigma(2) receptor ligands, and how these ligands have been used with a variety of in vitro and in vivo models to gain a greater understanding of the role this receptor plays in cancer.
Authors: S R Choi; B Yang; K Plössl; S Chumpradit; S P Wey; P D Acton; K Wheeler; R H Mach; H F Kung Journal: Nucl Med Biol Date: 2001-08 Impact factor: 2.408
Authors: Robert H Mach; Yunsheng Huang; Rebekah A Freeman; Li Wu; Suwanna Vangveravong; Robert R Luedtke Journal: Bioorg Med Chem Lett Date: 2004-01-05 Impact factor: 2.823
Authors: Allen F Brooks; Lindsey R Drake; Megan N Stewart; Brian P Cary; Isaac M Jackson; Dale Mallette; Andrew V Mossine; Peter J H Scott Journal: Pharm Pat Anal Date: 2015-12-16
Authors: Hilary E Nicholson; Walid F Alsharif; Anthony B Comeau; Christophe Mesangeau; Sebastiano Intagliata; Marco Mottinelli; Christopher R McCurdy; Wayne D Bowen Journal: J Pharmacol Exp Ther Date: 2018-12-07 Impact factor: 4.030
Authors: Jodi L Haller; Irina Panyutin; Aneeka Chaudhry; Chenbo Zeng; Robert H Mach; Joseph A Frank Journal: Mol Imaging Biol Date: 2012-06 Impact factor: 3.488
Authors: Rohit Bhat; James A Fishback; Rae R Matsumoto; Jacques H Poupaert; Christopher R McCurdy Journal: Bioorg Med Chem Lett Date: 2013-06-29 Impact factor: 2.823
Authors: James A Fishback; Abagail Rosen; Rohit Bhat; Christopher R McCurdy; Rae R Matsumoto Journal: J Pharm Biomed Anal Date: 2012-08-09 Impact factor: 3.935